Kristina Shkirkova1, Jeffrey L Saver1, Sidney Starkman2, Gregory Wong2, Julius Weng2, Scott Hamilton3, David S Liebeskind1, Marc Eckstein4,5, Samuel Stratton6,7,8, Frank Pratt9, Robin Conwit10, Nerses Sanossian11. 1. Stroke Center, Department of Neurology, University of California, Los Angeles. 2. Department of Emergency Medicine, University of California, Los Angeles. 3. Department of Neurology, Stanford University, Stanford, California. 4. Department of Emergency Medicine, University of Southern California, Los Angeles. 5. Los Angeles Fire Department, Los Angeles, California. 6. Department of Emergency Medicine, Harbor-University of California, Los Angeles Medical Center, Los Angeles. 7. Los Angeles EMS Agency, Los Angeles, California. 8. Orange County EMS Agency, Orange County, California. 9. Los Angeles County Department of Public Health, Los Angeles, California. 10. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. 11. Department of Neurology, University of Southern California, Los Angeles.
Abstract
Importance: Studies of neurological deterioration in stroke have focused on the subacute period, but stroke treatment is increasingly migrating to the prehospital setting, where the neurological course has not been well delineated. Objective: To describe the frequency, predictors, and outcomes of neurological deterioration among patients in the ultra-early period following ischemic stroke or intracranial hemorrhage. Design, Settings, and Participants: Exploratory analysis of the prehospital, randomized Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Trial conducted from 2005 to 2013 within 315 ambulances and 60 stroke patient receiving hospitals in Southern California. Participants were consecutively enrolled patients with suspected acute stroke who were transported by ambulance within 2 hours of stroke onset. Main Outcomes and Measures: The main outcome was neurological deterioration, defined as a worsening of 2 or more points on the Glasgow Coma Scale (GCS), a level of consciousness scale ranging from 3 to 15, with higher scores indicating more alertness. Imaging outcomes were ischemic or hemorrhagic injury extent identified during the first brain imaging scan. Outcomes at 3 months included global disability level (assessed using the modified Rankin Scale [mRS]; range, 0-6, with higher numbers indicating greater disability) and mortality. Results: Among the 1690 patients (99.4%), the mean (SD) age was 69.4 (13.5) years, and 43% were female. Final diagnoses were acute cerebral ischemia in 1237 patients (73.2%), intracranial hemorrhage in 386 patients (22.8%), and neurovascular mimic in 67 patients (4.0%). The median (interquartile range [IQR]) minutes between the last well-known time and GCS assessments were 23 (14-42) minutes for prehospital, 58 (46-79) minutes for ED arrival, and 149 (120-180) minutes for early ED course assessments. From prehospital to early postarrival, ultra-early neurological deterioration (U-END) occurred in 200 of 1690 patients (11.8%), more often among patients with intracranial hemorrhage than among those with acute cerebral ischemia (119 of 386 [30.8%] vs 75 of 1237 [6.1%], P < .001). Patterns of U-END were prehospital U-END without early recovery in 30 of 965 patients (3.1%), stable prehospital course but early ED deterioration in 49 of 965 patients (5.1%), and continuous deterioration in both prehospital and early ED phases in 27 of 965 patients (2.8%). Ultra-early neurological deterioration was associated with worse 3-month outcomes, including increased global disability (mRS score, 4.6 vs 2.4; P < .001), reduced functional independence (mRS score 0-2, 32 of 200 [16.0%] vs 844 of 1490 [56.6%]; P < .001), and increased mortality (87 of 200 [43.5%] vs 176 of 1490 [11.8%]; P < .001). Conclusions and Relevance: Ultra-early neurological deterioration occurs in 1 in 8 ambulance-transported patients with acute cerebrovascular disease, including 1 in 3 patients with intracranial hemorrhage and 1 in 16 patients with acute cerebral ischemia, and is associated with markedly reduced functional independence and increased mortality. Averting U-END may be a target for future prehospital therapeutics. Trial Registration: ClinicalTrials.gov Identifier: NCT00059332.
RCT Entities:
Importance: Studies of neurological deterioration in stroke have focused on the subacute period, but stroke treatment is increasingly migrating to the prehospital setting, where the neurological course has not been well delineated. Objective: To describe the frequency, predictors, and outcomes of neurological deterioration among patients in the ultra-early period following ischemic stroke or intracranial hemorrhage. Design, Settings, and Participants: Exploratory analysis of the prehospital, randomized Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Trial conducted from 2005 to 2013 within 315 ambulances and 60 strokepatient receiving hospitals in Southern California. Participants were consecutively enrolled patients with suspected acute stroke who were transported by ambulance within 2 hours of stroke onset. Main Outcomes and Measures: The main outcome was neurological deterioration, defined as a worsening of 2 or more points on the Glasgow Coma Scale (GCS), a level of consciousness scale ranging from 3 to 15, with higher scores indicating more alertness. Imaging outcomes were ischemic or hemorrhagic injury extent identified during the first brain imaging scan. Outcomes at 3 months included global disability level (assessed using the modified Rankin Scale [mRS]; range, 0-6, with higher numbers indicating greater disability) and mortality. Results: Among the 1690 patients (99.4%), the mean (SD) age was 69.4 (13.5) years, and 43% were female. Final diagnoses were acute cerebral ischemia in 1237 patients (73.2%), intracranial hemorrhage in 386 patients (22.8%), and neurovascular mimic in 67 patients (4.0%). The median (interquartile range [IQR]) minutes between the last well-known time and GCS assessments were 23 (14-42) minutes for prehospital, 58 (46-79) minutes for ED arrival, and 149 (120-180) minutes for early ED course assessments. From prehospital to early postarrival, ultra-early neurological deterioration (U-END) occurred in 200 of 1690 patients (11.8%), more often among patients with intracranial hemorrhage than among those with acute cerebral ischemia (119 of 386 [30.8%] vs 75 of 1237 [6.1%], P < .001). Patterns of U-END were prehospital U-END without early recovery in 30 of 965 patients (3.1%), stable prehospital course but early ED deterioration in 49 of 965 patients (5.1%), and continuous deterioration in both prehospital and early ED phases in 27 of 965 patients (2.8%). Ultra-early neurological deterioration was associated with worse 3-month outcomes, including increased global disability (mRS score, 4.6 vs 2.4; P < .001), reduced functional independence (mRS score 0-2, 32 of 200 [16.0%] vs 844 of 1490 [56.6%]; P < .001), and increased mortality (87 of 200 [43.5%] vs 176 of 1490 [11.8%]; P < .001). Conclusions and Relevance: Ultra-early neurological deterioration occurs in 1 in 8 ambulance-transported patients with acute cerebrovascular disease, including 1 in 3 patients with intracranial hemorrhage and 1 in 16 patients with acute cerebral ischemia, and is associated with markedly reduced functional independence and increased mortality. Averting U-END may be a target for future prehospital therapeutics. Trial Registration: ClinicalTrials.gov Identifier: NCT00059332.
Authors: Kristina Dupont Hougaard; Niels Hjort; Dora Zeidler; Leif Sørensen; Anne Nørgaard; Troels Martin Hansen; Paul von Weitzel-Mudersbach; Claus Z Simonsen; Dorte Damgaard; Hanne Gottrup; Kristina Svendsen; Peter Vestergaard Rasmussen; Lars R Ribe; Irene K Mikkelsen; Kartheban Nagenthiraja; Tae-Hee Cho; Andrew N Redington; Hans Erik Bøtker; Leif Østergaard; Kim Mouridsen; Grethe Andersen Journal: Stroke Date: 2013-11-07 Impact factor: 7.914
Authors: Jeffrey L Saver; Sidney Starkman; Marc Eckstein; Samuel Stratton; Frank Pratt; Scott Hamilton; Robin Conwit; David S Liebeskind; Gene Sung; Nerses Sanossian Journal: Int J Stroke Date: 2014-01-13 Impact factor: 5.266
Authors: Andrea Rocco; Marta Pasquini; Emanuella Cecconi; Gaia Sirimarco; Maria C Ricciardi; Edoardo Vicenzini; Marta Altieri; Vittorio Di Piero; Gian L Lenzi Journal: Stroke Date: 2007-02-22 Impact factor: 7.914
Authors: Lisa Shaw; Christopher Price; Sally McLure; Denise Howel; Elaine McColl; Paul Younger; Gary A Ford Journal: Emerg Med J Date: 2013-09-27 Impact factor: 2.740
Authors: Scott J Myers; Kamalesh P Ruppa; Lawrence J Wilson; Yesim A Tahirovic; Polina Lyuboslavsky; David S Menaldino; Zackery W Dentmon; George W Koszalka; Robert Zaczek; Raymond J Dingledine; Stephen F Traynelis; Dennis C Liotta Journal: J Pharmacol Exp Ther Date: 2021-09-07 Impact factor: 4.402
Authors: Alba Simats; Laura Ramiro; Raquel Valls; Helena de Ramón; Paula García-Rodríguez; Cyrille Orset; Laura Artigas; Teresa Sardon; Anna Rosell; Joan Montaner Journal: Neurotherapeutics Date: 2022-02-28 Impact factor: 6.088
Authors: Francisco Martín-Rodríguez; Raúl López-Izquierdo; Ancor Sanz-García; Carlos Del Pozo Vegas; Miguel Ángel Castro Villamor; Agustín Mayo-Iscar; José L Martín-Conty; Guillermo José Ortega Journal: J Med Syst Date: 2022-05-21 Impact factor: 4.920
Authors: Kristina Shkirkova; Samuel Schuberg; Emma Balouzian; Sidney Starkman; Marc Eckstein; Samuel Stratton; Franklin D Pratt; Scott Hamilton; Latisha Sharma; David S Liebeskind; Robin Conwit; Jeffrey L Saver; Nerses Sanossian Journal: Stroke Date: 2020-01-20 Impact factor: 7.914
Authors: Jun Gao; Changming Wen; Jun Sun; Di Chen; Donghuan Zhang; Ning Wang; Yifeng Liu; Jie Wang; Baochao Zhang Journal: Medicine (Baltimore) Date: 2022-04-29 Impact factor: 1.817